Anixa Biosciences (ANIX) Cash from Financing Activities (2010 - 2025)
Anixa Biosciences' (ANIX) quarterly Cash from Financing Activities came in at $350000.0 in Q4 2025, up 230.19% YoY from $106000.0 in Q4 2024, and down 81.86% on a QoQ basis from $1.9 million in Q3 2025.
Anixa Biosciences (ANIX) Cash from Financing Activities (2010 - 2025) Analysis & Trends
Anixa Biosciences (ANIX) has 16 years of Cash from Financing Activities data on file, last reported at $350000.0 in Q4 2025.
- Quarterly Cash from Financing Activities rose 230.19% year-over-year to $350000.0 in Q4 2025, while the trailing twelve-month figure through Oct 2025 was $2.3 million (down 33.24% YoY) and the FY2025 annual result came in at $2.3 million, down 33.24% from the prior year.
- Cash from Financing Activities declined to $350000.0 in Q4 2025, from $1.9 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $25.4 million in Q2 2021 to a low of -$384000.0 in Q4 2022.
- A 5-year average of $2.2 million and a median of $149000.0 in 2024 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 366.67% — and 2024, when it jumped 75333.33%.
- Tracing ANIX's Cash from Financing Activities over 5 years: stood at $144000.0 in 2021, then plunged by 366.67% to -$384000.0 in 2022, then soared by 172.66% to $279000.0 in 2023, then sank by 62.01% to $106000.0 in 2024, then soared by 230.19% to $350000.0 in 2025.
- The last three Cash from Financing Activities figures came in at $350000.0 (Q4 2025), $1.9 million (Q3 2025), and $18000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2025 | 350,000.00 |
| Oct 31, 2025 | 350,000.00 |
| Jul 31, 2025 | 1.93 Mn |
| Jul 31, 2025 | 1.93 Mn |
| Apr 30, 2025 | 18,000.00 |
| Apr 30, 2025 | 18,000.00 |
| Jan 31, 2025 | -17,000.00 |
| Jan 31, 2025 | -17,000.00 |
| Oct 31, 2024 | 106,000.00 |
| Oct 31, 2024 | 106,000.00 |
| Jul 31, 2024 | 149,000.00 |
| Jul 31, 2024 | 149,000.00 |
| Apr 30, 2024 | 897,000.00 |
| Apr 30, 2024 | 897,000.00 |
| Jan 31, 2024 | 2.26 Mn |
| Jan 31, 2024 | 2.26 Mn |
| Oct 31, 2023 | 279,000.00 |
| Oct 31, 2023 | 279,000.00 |
| Jul 31, 2023 | 3,000.00 |
| Jul 31, 2023 | 3,000.00 |